You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Baxter
Colorcon
AstraZeneca
McKesson
Express Scripts
Johnson and Johnson

Last Updated: April 10, 2020

DrugPatentWatch Database Preview

Claims for Patent: 10,182,984

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 10,182,984
Title:Targeted interferons demonstrate potent apoptotic and anti-tumor activities
Abstract: Novel chimeric moieties that show significant efficacy against cancers are provided. In certain embodiments the chimeric moieties comprise a targeting moiety attached to an interferon. In certain embodiments, the chimeric moieties comprise fusion proteins where an antibody that specifically binds to a cancer marker is fused to interferon alpha (IFN-.alpha.) or interferon beta (IFN-.beta.).
Inventor(s): Morrison; Sherie L. (Los Angeles, CA), Huang; Tzu-Hsuan (Libertyville, IL), Xuan; Caiyun (Newton, MA)
Assignee: The Regents of the University of California (Oakland, CA)
Application Number:15/359,456
Patent Claims:1. A method of inhibiting growth and/or proliferation of a rituximab-resistant cancer cell, said method comprising contacting said cancer cell with a chimeric construct comprising an interferon attached to an antibody that binds to a tumor-associated antigen, wherein said antibody is attached to said interferon by a linker where the amino acid sequence of said linker consists of the sequence SGGGGS (SEQ ID NO:81) or AEAAAKEAAAKAGS (SEQ ID NO:82), wherein said construct when contacted to said rituximab-resistant cancer cell results in the killing or inhibition of growth or proliferation of said cancer cell.

2. The method of claim 1, wherein said cancer cell is a metastatic cell.

3. The method of claim 1, wherein said cancer cell is in a solid tumor.

4. The method of claim 1, wherein said cancer cell is a breast cancer cell.

5. The method of claim 1, wherein said cancer cell is a B cell lymphoma.

6. The method of claim 1, wherein said cancer cell is cell produced by a cancer selected from the group consisting of a B cell lymphoma, lung cancer, a bronchus cancer, a colorectal cancer, a prostate cancer, a breast cancer, a pancreas cancer, a stomach cancer, an ovarian cancer, a urinary bladder cancer, a brain or central nervous system cancer, a peripheral nervous system cancer, an esophageal cancer, a cervical cancer, a melanoma, a uterine or endometrial cancer, a cancer of the oral cavity or pharynx, a liver cancer, a kidney cancer, a biliary tract cancer, a small bowel or appendix cancer, a salivary gland cancer, a thyroid gland cancer, a adrenal gland cancer, an osteosarcoma, a chondrosarcoma, a liposarcoma, a testes cancer, and a malignant fibrous histiocytoma.

7. The method of claim 1, wherein: said contacting comprises systemically administering said chimeric moiety to a mammal; or said contacting comprises administering said chimeric moiety directly into a tumor site; or said contacting comprises intravenous administration of said chimeric moiety.

8. The method of claim 1, wherein said cancer cell is a cancer cell in a human.

9. The method of claim 1, wherein said cancer cell is a cancer cell in a non-human mammal.

10. The method of claim 1, wherein said interferon is an interferon alpha.

11. The method of claim 1, wherein said interferon is an interferon beta.

12. The method of claim 1, wherein said construct is a recombinantly expressed fusion protein.

13. The method of claim 1, wherein said antibody specifically binds a marker selected from the group consisting of CD20, HER3, HER2/neu, MUC-1, G250, mesothelin, gp100, tyrosinase, and MAGE.

14. The method of claim 1, wherein said antibody is an antibody that binds CD20.

15. The method of claim 14, wherein said antibody that comprises the complementarity determining regions (CDRs) of anti-CD20 (rituximab).

16. The method of claim 14, wherein said antibody comprises the variable regions of anti-CD20 (rituximab).

17. The method of claim 1, wherein said antibody is an antibody that binds HER2.

Details for Patent 10,182,984

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial The Regents of the University of California (Oakland, CA) 2027-09-21 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Express Scripts
Colorcon
Baxter
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.